Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly’s Mounjaro and Zepbound. The stock dropped 8.2% in morning trading, enough to make it the ...
24/7 Wall St. on MSN32m
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
India Today on MSN1d
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss marketThe proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback